skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis



Review

(6794) Total Article Views


Authors: Paula Rackoff

Published Date May 2009 Volume 2009:4 Pages 207 - 213
DOI: http://dx.doi.org/10.2147/CIA.S4080

Paula Rackoff

Division of Rheumatology, Beth Israel Medical Center, New York, NY, USA

Abstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.

Keywords: osteoporosis, fracture




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: